Bacteriostatic Water · Research brief

Choose 5-Amino-1MQ Vial Size — Dosing and Research Guide

Real Peptides Research TeamEditorial

Updated July 6, 20267 min read

42 WORDS

Short answer

Key takeaways

A 50mg vial of 5-Amino-1MQ supports 10 days of standard research dosing (50mg daily) when reconstituted to 2mL, yielding 10 doses at 0.2mL per injection.
The 100mg vial doubles protocol duration to 20 days at the same concentration but must be consumed within 28 days post-reconstitution to avoid peptide degradation from hydrolysis.
Reconstitution volume changes injection volume per dose but does not increase total usable doses. Only starting peptide mass (vial size) determines dose count.
Post-reconstitution stability is 28 days maximum at 2–8°C regardless of vial size; freezing reconstituted peptide accelerates degradation rather than preserving potency.
Cost per milligram drops 15–25% with 100mg vials compared to 50mg vials, but only if the protocol consumes all peptide within the stability window. Unused peptide is wasted money.
Temperature excursions above 8°C compound degradation exponentially; repeated ambient temperature exposure can reduce effective stability from 28 days to under 20 days.
Bacteriostatic water is required for multi-week stability. Sterile water lacks the preservative needed to prevent bacterial contamination during repeated vial access over 14+ days.

Most researchers buying 5-Amino-1MQ for the first time choose the wrong vial size. Not because they misunderstand the compound, but because they underestimate how reconstitution volume and injection frequency affect usable doses per vial. A 50mg vial doesn't give you 50 doses. The math depends entirely on how you reconstitute it, what concentration you're targeting, and whether your protocol runs daily or every other day. Get this wrong and you're either reordering mid-protocol or discarding expensive peptide that degraded past its 28-day refrigerated stability window.

Our team has guided researchers through peptide procurement decisions across hundreds of protocols. The gap between ordering correctly and wasting money comes down to three calculations most suppliers never explain upfront.

How do you choose the right 5-Amino-1MQ vial size for research protocols?

To choose 5-Amino-1MQ vial size, calculate total protocol dosage needs first: multiply daily dose (typically 50mg) by protocol duration in days, then divide by vial concentration after reconstitution. A 50mg vial reconstituted in 2mL bacteriostatic water yields 25mg/mL. Supporting 25 days at 2mg daily dosing, or 50 days at 1mg daily. The 100mg vial doubles usable duration but requires consumption within the 28-day post-reconstitution stability window to avoid peptide degradation.

Here's what that calculation misses: 5-Amino-1MQ isn't dosed like semaglutide or BPC-157. The compound's mechanism. Inhibiting nicotinamide N-methyltransferase (NNMT), the enzyme that depletes cellular NAD+ reserves. Requires consistent plasma levels across multi-week protocols. Daily dosing at 50mg (the most common research standard) means a 50mg vial lasts exactly 25 days when reconstituted to 2mL at 25mg/mL concentration. Miss that stability window and the lyophilised powder's advantage. Long-term freezer storage at −20°C. Becomes irrelevant once you've added water. This article covers how vial size maps to protocol length, what reconstitution math determines usable doses, and which mistakes waste the most peptide before researchers notice.

How Vial Size Maps to Research Protocol Duration

5-Amino-1MQ vial size selection hinges on one constraint most buyers overlook: post-reconstitution peptide stability is 28 days maximum when refrigerated at 2–8°C, regardless of vial size. That 28-day clock starts the moment bacteriostatic water contacts the lyophilised powder. Not when you begin dosing. A 100mg vial offers twice the peptide mass of a 50mg vial, but if your protocol requires only 50mg total over 25 days, the remaining 50mg degrades unused. Our experience working with research teams shows this is the single most common procurement error: ordering more peptide than the protocol can consume within the stability window.

The standard research dose for 5-Amino-1MQ is 50mg daily, administered subcutaneously. At this frequency, a 50mg vial supports 25 days of dosing when reconstituted to a 2mL total volume (yielding 25mg/mL concentration. Each 0.1mL injection delivers 2.5mg, requiring 20 injections to deplete the vial). A 100mg vial at the same concentration supports 50 days. The constraint isn't peptide quantity. It's time. If your protocol runs longer than 28 days, you'll need to reconstitute a second vial partway through regardless of starting vial size, because the first vial's contents degrade past that window even if unused peptide remains.

Protocol planners frequently ask whether splitting a 100mg vial between two researchers extends value. It doesn't. Once reconstituted, both users draw from the same degrading solution. The 28-day limit applies to the vial contents, not individual syringes. Unused peptide in a reconstituted vial cannot be re-lyophilised or re-frozen. The only strategy that extends usable life is ordering multiple smaller vials and reconstituting them sequentially as each 28-day window closes.

Reconstitution Math: How Concentration Determines Dose Count

The number of usable doses per vial isn't fixed. It's calculated from reconstitution volume. 5-Amino-1MQ arrives as a lyophilised powder measured in milligrams of active peptide. Adding bacteriostatic water dissolves the powder into a solution, and the resulting concentration (mg/mL) determines how much liquid you draw per dose. Most researchers reconstitute 50mg vials with 2mL of bacteriostatic water, yielding 25mg/mL. At the standard 50mg daily dose, you'd inject 0.2mL (200 units on an insulin syringe). Giving you exactly 10 doses per 50mg vial, or 10 days of protocol coverage.

Here's where the math diverges from expectations. If you reconstitute that same 50mg vial with 5mL of water instead of 2mL, concentration drops to 10mg/mL. Now each 50mg dose requires 0.5mL (500 units). A volume five times larger. The vial still contains 50mg total peptide, but you can only draw 10 doses before the vial empties, exactly as before. Changing reconstitution volume changes injection volume per dose, not total doses available. The only variable that increases dose count is starting with more peptide mass. A larger vial.

Researchers frequently reconstitute to lower concentrations (10mg/mL or even 5mg/mL) to increase injection volume, which some find easier to measure accurately with insulin syringes. The trade-off: larger injection volumes mean more frequent vial access, which introduces contamination risk each time the stopper is punctured. Our team recommends reconstituting to the highest concentration your measurement tools can handle reliably. Typically 25mg/mL for 50mg vials or 50mg/mL for 100mg vials when using 0.01mL-increment syringes.

What Degrades 5-Amino-1MQ Before the Expiration Date

Peptide degradation isn't a binary event where the compound suddenly stops working on day 29. It's a progressive loss of potency that accelerates above specific temperature thresholds. 5-Amino-1MQ in lyophilised form remains stable for 12–24 months when stored at −20°C. Once reconstituted with bacteriostatic water, stability drops to 28 days at 2–8°C because water allows peptide bonds to undergo hydrolysis. The same chemical process that breaks down proteins in your body. Refrigeration slows this reaction; freezing the reconstituted solution after mixing doesn't stop it and actually worsens degradation through ice crystal formation that physically disrupts peptide structure.

Temperature excursions are the silent protocol killer. A single two-hour window at room temperature (20–25°C) won't render the peptide useless, but repeated exposure. Leaving the vial on the counter during multi-day dosing, for example. Compounds degradation exponentially. Peptides degrade roughly 2–3× faster at 25°C than at 4°C. If a vial spends 20% of its reconstituted life at ambient temperature instead of refrigerated, effective stability drops from 28 days to roughly 18–22 days. This isn't theoretical. We've seen research protocols fail at week three because vial handling introduced cumulative heat exposure the researcher never tracked.

Bacteriostatic water extends stability compared to sterile water because the 0.9% benzyl alcohol preservative inhibits bacterial growth during the multi-week window the vial remains punctured and accessed. Without it, contamination risk rises sharply after day 14. Even with bacteriostatic water, every needle puncture through the rubber stopper introduces potential contamination. Best practice: draw doses with a fresh needle each time, never reinsert a used needle into the vial, and discard any vial showing visible cloudiness or particulate matter regardless of calendar date.

5-Amino-1MQ Vial Size: 50mg vs 100mg Comparison

Before choosing between 50mg and 100mg vial sizes, calculate your protocol's total peptide requirement and compare it against the 28-day post-reconstitution stability limit. The table below shows how vial size, reconstitution volume, and dosing frequency interact to determine protocol coverage.

Vial Size	Reconstitution Volume	Concentration	Daily Dose (Standard)	Injection Volume per Dose	Total Doses Available	Protocol Duration Supported	Cost Efficiency (per mg)	Professional Assessment
50mg	2mL	25mg/mL	50mg (2mg peptide)	0.2mL (200 units)	10 doses	10 days	Baseline	Best for first-time researchers testing protocol tolerability or running short-duration (≤21 day) studies. Minimizes waste if protocol is discontinued early
50mg	5mL	10mg/mL	50mg (2mg peptide)	0.5mL (500 units)	10 doses	10 days	Baseline	Larger injection volume aids measurement precision with standard insulin syringes but increases contamination risk through more frequent vial access. Use only if measurement accuracy is a concern
100mg	2mL	50mg/mL	50mg (2mg peptide)	0.1mL (100 units)	20 doses	20 days	15–25% lower	Optimal for protocols running 14–28 days. Maximum peptide utilization within stability window and lowest per-dose cost, but requires precise 0.1mL measurement capability
100mg	4mL	25mg/mL	50mg (2mg peptide)	0.2mL (200 units)	20 doses	20 days	15–25% lower	Balances measurement ease with protocol coverage. Recommended for most standard 21–28 day research cycles when using 0.01mL-increment syringes
100mg	5mL	20mg/mL	50mg (2mg peptide)	0.25mL (250 units)	20 doses	20 days	15–25% lower	Slightly easier measurement than 25mg/mL but offers no practical advantage unless syringe increments are coarse. Adds unnecessary liquid volume for most use cases

What If: 5-Amino-1MQ Vial Size Scenarios

What If My Protocol Runs Longer Than 28 Days?

Order multiple smaller vials instead of one large vial. Reconstitute the first vial, use it completely within 28 days, then reconstitute the second vial to continue the protocol. A 60-day protocol at 50mg daily requires two 100mg vials reconstituted sequentially, not one 200mg vial (which doesn't exist) or one 100mg vial stretched past its stability limit. Attempting to extend a single vial's life by refrigerating it longer than 28 days risks running the entire second month of your protocol on degraded peptide with unknown potency.

What If I Accidentally Left the Reconstituted Vial at Room Temperature Overnight?

Discard it if it sat out longer than 8–12 hours. Peptide degradation accelerates 2–3× at 20–25°C compared to refrigeration, and structural changes from prolonged heat exposure are irreversible. A vial left out for 10 hours has effectively

All compounds discussed on this page are sold for research use only and are not for human consumption.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

A 50mg vial lasts 10 days when dosed at the standard 50mg daily research protocol and reconstituted to 2mL (25mg/mL concentration). Each dose requires 0.2mL injection volume, yielding 10 total doses per vial. If your protocol uses a lower daily dose or alternate-day dosing, duration extends proportionally — but the vial must still be consumed within 28 days post-reconstitution to avoid peptide degradation.

No — freezing reconstituted peptide accelerates degradation rather than preserving it. Ice crystal formation physically disrupts peptide bonds, causing irreversible structural damage. Once mixed with bacteriostatic water, 5-Amino-1MQ must be stored at 2–8°C and used within 28 days. Only lyophilised (powdered) peptide should be frozen at −20°C for long-term storage before reconstitution.

The 100mg vial typically costs 15–25% less per milligram than the 50mg vial, translating to roughly 30–50% lower per-dose cost for protocols that consume the full vial within the 28-day stability window. However, this savings disappears if your protocol requires less than 100mg total — unused peptide that degrades past 28 days post-reconstitution represents pure waste, making the smaller vial the more economical choice for shorter studies.

Visible signs of degradation include cloudiness, discoloration, or particulate matter floating in the solution — any of these warrant immediate disposal. However, peptide degradation often occurs without visible changes; potency loss from hydrolysis and temperature exposure is invisible to the naked eye. This is why the 28-day refrigerated stability limit exists as a safety threshold — beyond that point, degradation has progressed enough to compromise research reliability even if the solution looks clear.

Buy two 50mg vials and reconstitute them sequentially. A single 100mg vial covers only 20 days at standard 50mg daily dosing, forcing you to reconstitute a second vial anyway for days 21–30. Two 50mg vials reconstituted 15 days apart (first on day 1, second on day 16) ensure each vial is consumed well within its 28-day stability window, whereas a 100mg vial requires mid-protocol reconstitution of additional peptide regardless.

A single missed dose does not compromise peptide stability in the vial — it simply extends your protocol by one day. The 28-day post-reconstitution clock continues regardless of dosing adherence. If you miss multiple doses across several days, recalculate whether your remaining peptide will last through the adjusted protocol end date while staying within the stability window. Missing five doses on a 100mg vial (20 total doses) means you have 15 days of peptide remaining, but it must still be used before day 28 post-reconstitution.

Reconstitution volume determines injection volume per dose, which affects measurement precision and contamination risk. A 50mg vial reconstituted to 2mL requires 0.2mL per dose (easy to measure accurately with standard insulin syringes), while the same vial reconstituted to 5mL requires 0.5mL per dose (larger volume, but also more vial punctures and higher contamination exposure over the protocol duration). Total doses available remains identical — only the liquid volume drawn per injection changes.

Long-term research protocols are limited by peptide stability post-reconstitution, not by the compound's safety profile in controlled research settings. Protocols extending beyond 30 days require sequential reconstitution of multiple vials rather than extending a single vial past its 28-day refrigerated stability limit. Researchers planning extended studies should design vial sequencing schedules that maintain peptide integrity throughout the full protocol duration — typically reconstituting a fresh vial every 20–25 days.

Yes, but both subjects must complete dosing within 28 days of the single reconstitution event — the stability clock applies to the vial contents, not individual syringes or subjects. If Subject A uses 50mg over 10 days and Subject B uses the remaining 50mg over days 11–20, this works. If their protocols are staggered such that Subject B begins dosing on day 30, the peptide will have degraded past acceptable potency regardless of how much remains in the vial.

Use bacteriostatic water containing 0.9% benzyl alcohol as a preservative — never sterile water or saline. The preservative inhibits bacterial growth during the multi-week period the vial remains punctured and accessed repeatedly for dosing. Sterile water lacks this preservative, creating contamination risk after 7–10 days even under refrigeration. Bacteriostatic water is the standard for all multi-dose peptide reconstitution and is required to safely extend usability to the full 28-day stability window.

5-Amino-1MQ follows the same vial sizing and stability principles as other lyophilised research peptides: smaller vials (50mg) suit short protocols or first-time testing, while larger vials (100mg) offer cost efficiency for longer studies that consume all peptide within 28 days post-reconstitution. The compound's specific mechanism — NNMT inhibition to preserve cellular NAD+ — requires consistent daily dosing across multi-week protocols, making vial sequencing and stability management more critical than with single-dose or infrequent-dosing peptides.

The most common mistake is buying a 100mg vial for a protocol that consumes only 60–70mg total, leaving 30–40mg to degrade unused past the 28-day stability window. Researchers often prioritize per-milligram cost without calculating total protocol peptide requirements first. The correct approach: multiply daily dose by protocol duration to determine total peptide needed, then choose the smallest vial size that covers that total — only selecting larger vials if the protocol duration falls within the 28-day post-reconstitution limit.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA